Vasculitis & polymyalgia rheumatica

Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study

Rheumatology (Oxford)Published Retrospective case-control study

Authors' conclusion

ATD-induced AAV were mainly MPA with MPO-ANCA, but double MPO- and PR3-ANCA positivity was frequent. The most common manifestations were skin and musculoskeletal manifestations. ATD-induced MPA were less severe and showed a lower risk of relapse than primary MPA.

Study context

Population
Patients with ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs, multicentre45 anti-thyroid drugs (ATD)-induced AAV, 24 microscopic polyangiitis (MPA)
Participants
24 vs 96
Comparison
ATD-induced MPA vs matched primary MPA
  • ATD-induced MPAn = 24
  • Primary MPAn = 96reference
Outcome
Characteristics of ATD-induced AAV
Methodological detailsmulticentre, matched by gender and year of diagnosis (four controls per case)
  • Multicentre
  • Matched by gender and year of diagnosis (four controls per case)

Main finding

As reported in the abstract

ANCA positive
44 patients (98%)
MPO-ANCA
21 (47%)
PR3-ANCA
6 (13%)
Double positive myeloperoxidase (MPO)- and PR3-ANCA
15 (33%)
Skin involvement
64%
Arthralgia
51%
Glomerulonephritis
20%
ATD discontinued
98%
Remission after ATD discontinuation alone
7 (16%)
Remission with GC plus RTX
11 (30%)
Remission with GC plus CYC
4 (11%)
ATD reintroduced, without subsequent relapse
7 (16%)

Observational data: associations, not effects.

Further findings

Age at diagnosis

P < 0.001

Cutaneous involvement

P = 0.007

Kidney involvement

P = 0.02

OutcomeaHR (95% CI)P value
Relapse0.07 (0.01–0.65)P = 0.019

Original publication

Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study. Rheumatology (Oxford). Published 24 June 2023. doi:10.1093/rheumatology/kead319

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.